277 related articles for article (PubMed ID: 30679619)
1. Application of the Transcriptional Disease Signature (TDSs) to Screen Melanoma-Effective Compounds in a Small Fish Model.
Lu Y; Boswell W; Boswell M; Klotz B; Kneitz S; Regneri J; Savage M; Mendoza C; Postlethwait J; Warren WC; Schartl M; Walter RB
Sci Rep; 2019 Jan; 9(1):530. PubMed ID: 30679619
[TBL] [Abstract][Full Text] [Related]
2. Expression Signatures of Cisplatin- and Trametinib-Treated Early-Stage Medaka Melanomas.
Klotz B; Kneitz S; Lu Y; Boswell W; Postlethwait J; Warren W; Walter RB; Schartl M
G3 (Bethesda); 2019 Jul; 9(7):2267-2276. PubMed ID: 31101653
[TBL] [Abstract][Full Text] [Related]
3. Transcriptional background effects on a tumor driver gene in different pigment cell types of medaka.
Abdulsahib S; Boswell W; Boswell M; Savage M; Schartl M; Lu Y
J Exp Zool B Mol Dev Evol; 2024 May; 342(3):252-259. PubMed ID: 37877158
[TBL] [Abstract][Full Text] [Related]
4. Comparative analysis of melanoma deregulated miRNAs in the medaka and Xiphophorus pigment cell cancer models.
Mishra RR; Kneitz S; Schartl M
Comp Biochem Physiol C Toxicol Pharmacol; 2014 Jun; 163():64-76. PubMed ID: 24462553
[TBL] [Abstract][Full Text] [Related]
5. Expression signatures of early-stage and advanced medaka melanomas.
Klotz B; Kneitz S; Regensburger M; Hahn L; Dannemann M; Kelso J; Nickel B; Lu Y; Boswell W; Postlethwait J; Warren W; Kunz M; Walter RB; Schartl M
Comp Biochem Physiol C Toxicol Pharmacol; 2018 Jun; 208():20-28. PubMed ID: 29162497
[TBL] [Abstract][Full Text] [Related]
6. A mutated EGFR is sufficient to induce malignant melanoma with genetic background-dependent histopathologies.
Schartl M; Wilde B; Laisney JA; Taniguchi Y; Takeda S; Meierjohann S
J Invest Dermatol; 2010 Jan; 130(1):249-58. PubMed ID: 19609310
[TBL] [Abstract][Full Text] [Related]
7. Whole Body Melanoma Transcriptome Response in Medaka.
Schartl M; Shen Y; Maurus K; Walter R; Tomlinson C; Wilson RK; Postlethwait J; Warren WC
PLoS One; 2015; 10(12):e0143057. PubMed ID: 26714172
[TBL] [Abstract][Full Text] [Related]
8. Integrating LINCS Data to Evaluate Cancer Transcriptome Modifying Potential of Small-molecule Compounds for Drug Repositioning.
Zhao Y; Liu Y; Bai H
Comb Chem High Throughput Screen; 2021; 24(9):1340-1350. PubMed ID: 33109034
[TBL] [Abstract][Full Text] [Related]
9. Automated in vivo screen in zebrafish identifies Clotrimazole as targeting a metabolic vulnerability in a melanoma model.
Precazzini F; Pancher M; Gatto P; Tushe A; Adami V; Anelli V; Mione MC
Dev Biol; 2020 Jan; 457(2):215-225. PubMed ID: 30998907
[TBL] [Abstract][Full Text] [Related]
10. Multidimensional Screening Platform for Simultaneously Targeting Oncogenic KRAS and Hypoxia-Inducible Factors Pathways in Colorectal Cancer.
Bousquet MS; Ma JJ; Ratnayake R; Havre PA; Yao J; Dang NH; Paul VJ; Carney TJ; Dang LH; Luesch H
ACS Chem Biol; 2016 May; 11(5):1322-31. PubMed ID: 26938486
[TBL] [Abstract][Full Text] [Related]
11. Histopathologic features of melanocytic tumors in
Sugiyama A; Schartl M; Naruse K
J Toxicol Pathol; 2019 Apr; 32(2):111-117. PubMed ID: 31092978
[TBL] [Abstract][Full Text] [Related]
12. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma.
Stegmaier K; Wong JS; Ross KN; Chow KT; Peck D; Wright RD; Lessnick SL; Kung AL; Golub TR
PLoS Med; 2007 Apr; 4(4):e122. PubMed ID: 17425403
[TBL] [Abstract][Full Text] [Related]
13. High-Throughput Screening and Triage Assays Identify Small Molecules Targeting c-MYC in Cancer Cells.
Kallal LA; Waszkiewicz A; Jaworski JP; Della Pietra A; Berrodin T; Brady P; Jurewicz AJ; Zeng X; Payne L; Medina JR; Doepner-Buser C; Mangatt B
SLAS Discov; 2021 Feb; 26(2):216-229. PubMed ID: 33482073
[TBL] [Abstract][Full Text] [Related]
14. MITF-M plays an essential role in transcriptional activation and signal transduction in Xiphophorus melanoma.
Delfgaauw J; Duschl J; Wellbrock C; Froschauer C; Schartl M; Altschmied J
Gene; 2003 Nov; 320():117-26. PubMed ID: 14597395
[TBL] [Abstract][Full Text] [Related]
15. Synthetic lethal screening with small-molecule inhibitors provides a pathway to rational combination therapies for melanoma.
Roller DG; Axelrod M; Capaldo BJ; Jensen K; Mackey A; Weber MJ; Gioeli D
Mol Cancer Ther; 2012 Nov; 11(11):2505-15. PubMed ID: 22962324
[TBL] [Abstract][Full Text] [Related]
16. Conserved expression signatures between medaka and human pigment cell tumors.
Schartl M; Kneitz S; Wilde B; Wagner T; Henkel CV; Spaink HP; Meierjohann S
PLoS One; 2012; 7(5):e37880. PubMed ID: 22693581
[TBL] [Abstract][Full Text] [Related]
17. Differential expression of transposable elements in the medaka melanoma model.
Helmprobst F; Kneitz S; Klotz B; Naville M; Dechaud C; Volff JN; Schartl M
PLoS One; 2021; 16(10):e0251713. PubMed ID: 34705830
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the putative tumor suppressor gene cdkn2ab in pigment cells and melanoma of Xiphophorus and medaka.
Regneri J; Klotz B; Wilde B; Kottler VA; Hausmann M; Kneitz S; Regensburger M; Maurus K; Götz R; Lu Y; Walter RB; Herpin A; Schartl M
Pigment Cell Melanoma Res; 2019 Mar; 32(2):248-258. PubMed ID: 30117276
[TBL] [Abstract][Full Text] [Related]
19. Transcriptional Regulation of Müllerian Inhibiting Substance (MIS) and Establishment of a Gonadal Somatic Cell Line Using
Kawabe T; Kariya H; Hara S; Shirozu T; Shiraishi E; Mukai K; Yazawa T; Inoue S; Kitano T
Front Endocrinol (Lausanne); 2020; 11():578885. PubMed ID: 33133021
[TBL] [Abstract][Full Text] [Related]
20. Establishment of HRAS(G12V) transgenic medaka as a stable tumor model for in vivo screening of anticancer drugs.
Matsuzaki Y; Hosokai H; Mizuguchi Y; Fukamachi S; Shimizu A; Saya H
PLoS One; 2013; 8(1):e54424. PubMed ID: 23342156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
